tbuckley/cabot-search huggingface dataset:
AB0969 SIGNIFICANT RELATIONSHIP OF TRACE ELEMENTS WITH OBJECTIVE SERUM INFLAMMATORY MARKERS IN SPONDYLOARTHRITIS
Authors: S. Tsiami, L. Schomburg, T. S. Chillon, E. Rousis, U. Gröber, X. Baraliakos
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Selenium (Se) is an essential micronutrient and is identified as an important element for the antioxidant defense. Through its incorporation into selenoproteins, Se is involved in the regulation of oxidative stress, redox state and other important cellular processes, including those involved in innate and adaptive immune response reactions (1). In addition, copper (Cu) and zinc (Zn) are integral functional components of many enzymes and transcriptional regulatory proteins affecting inflammatory responses (2). <h3>Objectives:</h3> To investigate the micronutrient status of selenium and other trace elements in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). <h3>Methods:</h3> The study included patients with the clinical diagnosis of axSpA or PsA from the prospective daily practice observational cohort (LORE). Serum samples from the biomaterial bank were collected and trace elements were measured using Total reflection X-ray fluorescence (TXRF). In addition, the Se transporter SELENOP and activity of glutathione peroxidase-3 (GPx3) were quantified. <h3>Results:</h3> Eighty-four patients with axSpA (60 males, median age 43 years, range 20-74) and 76 patients with PsA (32 males, median age 53 years, range 22-76) were included. Serum Se was relatively low as compared to healthy adults (3), but no differences in the concentrations of serum Cu, Se or Zn were detected between axSpA and PsA. Significant positive correlations were observed between the three biomarkers of Se status (Se, SELENOP and GPx3). Spearman correlation analysis indicated that SELENOP and Zn correlate negatively with c-reactive protein (CRP) in patients with axSpA (r=-0.34, p=0.0013 and r=-0.33, p=0.0021 respectively), whereas Cu correlated positively (r=0.43, p&lt;0.001) (Figure 1). Similar results were found for inflammation measured by the erythrocyte sedimentation rate (ESR). <h3>Conclusion:</h3> Se and Zn status are negatively associated with inflammatory burden in axSpA and PsA, whereas Cu shows a positive association. SELENOP proved as sensitive biomarker for objective inflammatory and should be further investigated during therapy with bDMARD with respect to alterations in inflammatory burden. <h3>REFERENCES:</h3> [1] Behne D, Wolters W. Distribution of selenium and glutathione peroxidase in the rat. <i>J Nutr</i>. 1983;113(2):456-461. doi:10.1093/JN/113.2.456 [2] Chan S, Gerson B, Subramaniam S (1998) The role of copper, molybdenum, selenium, and zinc in nutrition and health. Clin Lab Med 18(4):673–685 [3] Hughes DJ, et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer. 2015 Mar 1;136(5):1149-61. doi: 10.1002/ijc.29071. Epub 2014 Jul 21. PMID: 25042282. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1193 DISTINCT CLINICAL TRAJECTORIES OF GASTROINTESTINAL PROGRESSION AMONG PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: J. Perin, M. Hughes, F. Wigley, C. Mecoli, J. Paik, A. Gelber, L. Hummers, A. A. Shah, S. Zeger, Z. Mcmahan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is very heterogenous in its clinical presentation. Common manifestations cluster together defining subgroups of disease. <h3>Objectives:</h3> The goal of this investigation is to characterize and define gastrointestinal (GI) phenotypes. <h3>Methods:</h3> We examine a well-established SSc patient cohort, with a modified Medsger GI severity score measured over time, to determine heterogeneity in disease progression. Growth mixture models are used to estimate the phenotype for each patient as well as the trajectory of disease severity over time. We compare the characteristics of estimated phenotypes using non-parametric statistics, and linear and logistic regression to compare patient characteristics between phenotypes while adjusting for disease duration. <h3>Results:</h3> We examined GI organ system involvement from 2696 patients with SSc with at least two Medsger GI scores, identifying four unique phenotypes. The most common phenotype (n=2325) (Cluster C, "Stable") had an average score of 1 that was consistent over time. Two phenotypes were progressive [Cluster A, "Early Progressive" (n=142) and Cluster D, "Late Progressive" (n=115)] and had an initial average score of 1. The Progressive/Fibrotic group increased initially and stabilized, and the Progressive/Vascular group worsened slowly over time. A fourth phenotype [Cluster B, "Most Severe GI"; (n=114)] had the most severe GI disease initially (an initial average Medsger GI score of just below 3) and had the highest mortality, but GI severity improved over time even for this cluster after accounting for disease duration and survival. Significant differences between phenotypes were identified, including autoantibody and mortality status. <h3>Conclusion:</h3> Clinically distinct GI phenotypes exist among patients with SSc. These phenotypes are not only distinguished by GI and extra-intestinal SSc clinical complications, but they are also temporally distinct. Distinct autoantibody profiles associate strongly with more severe GI disease. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Jamie Perin: None declared, Michael Hughes: None declared, Frederick Wigley: None declared, Chris Mecoli: None declared, Julie Paik: None declared, Allan Gelber: None declared, Laura Hummers: None declared, Ami A. Shah: None declared, Scott Zeger: None declared, Zsuzsanna McMahan ZM is a consultant for Boehringer Ingelheim.
AB1277 HIGHER SERUM FIBROBLAST GROWTH FACTOR 2 LEVELS ARE PRONE TO APPEAR IN YOUNGER PATIENTS WITH TAKAYASU’S ARTERITIS
Authors: N. Gao, L. Pan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Pathogenesis of TAK is still unclear. Multiple immune cells and cytokines participate in TAK. Fibroblast growth factor 2 (FGF2) is a heparin-binding growth factor with multiple functions. It is involved in cell migration and differentiation, developmental processes and angiogenesis. The angiogenic property of FGF2 is to promote proliferation of endothelial cells, mitogenesis of smooth muscle cells and fibroblasts. Other physiological roles include inflammation. <h3>Objectives:</h3> Takayasu's arteritis (TAK) is a rare large vessel vasculitis. The fibroblast growth factor 2(FGF2) has angiogenic property. This study aims to investigate expression of FGF2 in TAK patients. <h3>Methods:</h3> Serum cytokines of 48 patients with TAK and 32 healthy controls were detected using cytokine cytometric bead array. The percentage of T cell subsets of TAK patients were analyzed by flow cytometry analysis. Immunohistochemical staining analysis were used to detect FGF expression in the aortic wall of 3 TAK patients and 3 atherosclerosis patients. <h3>Results:</h3> Serum level of FGF2 were significantly elevated in patients with TAK compared to controls [40.22 (29.88, 60.01) pg/ml vs. 26.51(21.28, 30.08) pg/ml, p &lt; 0.001].Serum FGF2 level was negatively correlated to age (r = -0.313, p = 0.030),age of TAK onset(r=-0.329, p = 0.023) and positively correlated to cytokines [G-CSF (r = 0.361, p = 0.002), CCL2(r = 0.251, p = 0.034), CCL3(r = 0.572, p &lt; 0.001), IL-4(r = 0.421, p &lt; 0.001), IL-8(r = 0.646, p &lt; 0.001), IL-17(r = 0.812, p &lt; 0.001)Furthermore, we found marked expression of FGF2 was shown in aortic lesions of patients with TAK compared with those of atherosclerosis(5.380% ± 0.986% vs. 0.019% ± 0.012%, P = 0.011). <h3>Conclusion:</h3> Higher serum FGF2 levels are prone to appear in younger TAK patients with Takayasu's arteritis. FGF2 might be involved in the pathogenesis in TAK. <h3>REFERENCES:</h3> [1] Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology (Oxford). 2019;58:206–219. [2] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235-53. [3] Fukui S, Kuwahara-Takaki A, Ono N, Sato S, Koga T, Kawashiri SY, et al. Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis. Sci Rep 2019;9:688. [4] Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, et al. Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. Clin Exp Rheumatol 2020;38 Suppl 124(2):23-30. [5] Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33(8):1129-34. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0066 UNRAVELING KEY FACTORS IN COVID-19 VACCINATION AMONG RHEUMATOID ARTHRITIS PATIENTS: A LANDMARK MONOCENTRIC INVESTIGATION
Authors: H. Elhani, H. Toufik, L. Taoubane, N. EL Ouardi, A. Majjad, A. Bezza
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The emergence of the COVID-19 pandemic has swiftly raised concerns about the heightened vulnerability of patients with autoimmune diseases, notably rheumatoid arthritis (RA), due to their immunocompromised status. In this context, the Moroccan Society of Rheumatology early on recommended COVID-19 vaccination for this at-risk population. However, comprehending the factors influencing the decision to get vaccinated in RA patients is essential. This study aims to assess the COVID-19 vaccination rate in RA patients and identify factors associated with non-vaccination. Such an analysis will contribute to guiding the establishment of more effective vaccination strategies tailored to the specific needs of this population. <h3>Objectives:</h3> Evaluate COVID-19 vaccination rates in rheumatoid arthritis patients, identifying factors influencing non-vaccination to inform targeted strategies for optimizing immunization uptake in this vulnerable population. <h3>Methods:</h3> This is a monocentric cross-sectional study conducted from January 2022 to January 2023, involving adult patients meeting the ACR/EULAR 2010 criteria for rheumatoid arthritis. Sociodemographic data, COVID-19 vaccination status, and RA characteristics were collected using a questionnaire administered by the treating physician. Logistic regression analysis was employed to examine the association between RA characteristics and COVID-19 vaccination status. Statistical analysis was performed using the JAMOVI software. <h3>Results:</h3> A total of 200 patients were included, with 81.5% being female. The mean age was 56 ± 10.8 years. The average disease duration was 8.4 years ± 7.29. Among these patients, 169 (84.9%) were vaccinated against COVID-19. Among the unvaccinated patients, 83.3% (25) were female (p = 0.76), and the mean age was 43 ± 5.73 (p = 0.51). COVID-19 vaccination was statistically associated with the duration of RA (OR = 1.03 per additional year of disease duration, p = 0.03), disease activity measured by DAS28-CRP (OR = 0.66 per additional unit of DAS28-CRP, p = 0.03), and treatment with biologics (OR = 1.23, p = 0.03). <h3>Conclusion:</h3> These results underscore the importance of an individualized approach in the vaccination strategy for this at-risk population. Future vaccination guidelines must imperative consider these factors to enhance the protection of patients with rheumatoid arthritis while contributing to the battle against virus spread. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1028 EFFECT OF RENIN-ANGIOTENSIN-SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD STUDY
Authors: X. Zhang, J. Zhao, H. Huang, Y. Fan, Z. Zhang
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Renin-angiotensin-system inhibitors (RASi) have been recommended for patients with diabetic or nondiabetic nephropathy, but the studies focused on RASi in lupus nephritis are scaring. <h3>Objectives:</h3> To assess the effect of RASi for LN in a Chinese real-world cohort. <h3>Methods:</h3> The primary outcome was proteinuria partial recovery (PPR) rate at 6 months, other outcomes including the rate of complete remission (CR), total remission (TR), decline and decline rate of proteinuria. LN remission was compared by Chi-square tests. Inverse probability of treatment weighting (IPTW) was adopted to adjust for the baseline characteristics. Cox regression analysis was also performed. <h3>Results:</h3> There were 233 LN patients enrolled in the study, with 156 receiving RASi (RASi group) and 77 patients without exposure to RASi (no RASi group). At 6 months, 70.6% patients in RASi group and 81.7% in no RASi group reached PPR (p=0.139). Rates of CR and TR were significantly higher in no RASi group (CR: 32.7% vs. 50.8%, p=0.036; TR: 57.6% vs. 77.2%, p=0.017). At 12 months, the PPR rate was also significantly higher in no RASi group than RASi group (97.3% vs. 89.7%, p=0.030), but the rates of CR and TR were similar (CR: 50.2% vs. 58.3%, p=0.374; TR: 66.4% vs. 78.5%, p=0.131). The reduction of UTP and UTP declining rate were not significantly different between two groups. Meanwhile, the serum SCr was maintained stable and not different between two groups. The SLEDAI-2K and dose of prednisolone were also not statistically different. <h3>Conclusion:</h3> Our real-world comparative study suggested that LN patients may not benefit from RASi treatment. and the results need to be interpreted with caution. Further high-quality randomized controlled trials and long-term follow-up are required to evaluate the RASi effects on proteinuria and renal prognosis. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0642 LOCALISED JOINT LESIONS IN THE WRIST OF PATIENTS WITH RHEUMATOID ARTHRITIS ARE DIFFICULT TO EVALUATE ON PHYSICAL EXAMINATION
Authors: T. Ogura, N. Hayashi, C. Imaizumi, Y. Takakura, Y. Minegishi, T. Kagtagiri, H. Kameda
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Joint examination is an essential basic evaluation in treating rheumatoid arthritis (RA). However, physical examination and ultrasound (US) findings are not always consistent. Subclinical synovitis of the wrist is thought to be particularly common in RA patients [1]. <h3>Objectives:</h3> We aimed to clarify the discrepancy between physical examination and US findings on the wrist of RA patients. <h3>Methods:</h3> We compared physical examination with US findings in 235 RA patients who underwent US of the bilateral wrist joints. US was performed in three regions (radial, median, and ulnar) on dorsal longitudinal views, and US synovitis was defined as Gray Scale (GS) grade 2 or higher and/or Power Doppler Scale (PD) grade 1 or higher using a 4-point semiquantitative method from 0-3. Subclinical synovitis (SS) was defined as joints with ultrasound synovitis without swelling or tenderness on physical examination, and clinical synovitis (CS) was defined as joints with US synovitis with swelling and/or tenderness on physical examination. We analyzed the factors that lead to SS using a generalized linear mixed model. <h3>Results:</h3> SS was identified in 100 joints (21%), and CS in 129 joints (27%) of the total 470 joints bilaterally. Comparing the two groups, the total score of the three regions was significantly lower in SS than CS for both GS and PD (median 2 vs. 5 and 1 vs. 4, respectively, p&lt;0.001). In addition, SS showed less counts of involved areas in each wrist joint than CS (median: 1 vs. 3, p&lt;0.001). Furthermore, when radial and median regions were combined for the analyses of wrist synovitis localised in one or two regions, but not in all three regions, the synovitis only on the radial and/or median sides was detected in 55 of 100 SS joints (55%) and 26 of 129 CS joints (20%) (p&lt;0.001), while the synovitis only on the ulnar side was observed in 18 joints (18%) and 13 joints (10%) in SS and CS, respectively (p=0.12). When the following factors (age, gender, disease duration, body mass index, DAS28-CRP and US synovitis findings) were included, SS was significantly associated with DAS28-CRP (OR=0.29, 95% CI [0.14, 0.57], p&lt;0.001), total US score (OR=0.63, 95% CI [0.43, 0.92], p=0.016) and synovitis only on the radial and/or median sides (OR=4.29, 95% CI [1.01, 18.16], p=0.047). <h3>Conclusion:</h3> It was suggested that arthritis is difficult to detect on examination in the wrist joints of RA patients when the lesions are localised only to the radial and/or median sides. <h3>REFERENCES:</h3> [1] Nakagomi D et al. Arthritis Rheum. 2013; 65: 890-8. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0925 VISUAL MANIFESTATIONS IN GIANT CELL ARTERITIS: IDENTIFICATION OF RISK FACTORS FROM THE ARTESER REGISTRY
Authors: J. Molina-Collada, M. Dominguez-Alvaro, R. B. Melero-González, E. Fernández-Fernández, M. Silva-Díaz, J. A. Valero Jaimes, I. González, J. Sanchez-Martín, J. Narváez, I. Calvo, J. Mendizabal, L. Abasolo, J. Loricera, A. Ruiz Román, P. Moya, M. Tortosa Cabañas, P. Estrada, F. J. Prado, S. Castañeda, R. Blanco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> <h3>Objectives:</h3> To determine the prevalence and predictive factors of visual manifestations in a large registry of patients with GCA. <h3>Methods:</h3> ARTESER is a large Spanish multicenter registry supported by the Spanish Society of Rheumatology. It includes patients with GCA from across the entire country diagnosed between June 2013 and March 2019. The variables collected at diagnosis were demographics, clinical manifestations (including all visual manifestations), laboratory, temporal artery biopsy, and imaging findings (ultrasound, FDG-PET/CT, MRI angiography, CT angiography). Patients with and without visual involvement were compared in a bivariate analysis. Multivariate logistic regression was performed to determine potential predictive factors of visual manifestations. <h3>Results:</h3> The study population comprised 1636 GCA patients, of whom 599 (36.6%) presented visual manifestations. Anterior ischemic optic neuropathy was the most frequent (n=274 of 599; 45.7%) ocular complication. Clinical findings of patients with and without visual involvement are shown in Table 1. The independent predictors that increased the risk (OR; 95% confidence interval) of visual involvement were older age (1.027; 1.009-1.045) and jaw claudication (1.724; 1.325-2.243). The variables associated with a reduced risk were polymyalgia rheumatica (0.541; 0.414-0.708), fever (0.373; 0.264-0.527), longer symptom duration (0.946; 0.909-0.985), and higher erythrocyte sedimentation rate (ESR) (0.992; 0.988-0.997), common features of patients with large vessel-GCA (Table 2). <h3>Conclusion:</h3> One-third of GCA patients present visual manifestations at diagnosis. Older age and jaw claudication are independent predictors of visual manifestations, whereas polymyalgia rheumatica, fever, longer symptom duration, and high ESR reduce the risk of visual involvement. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1414 PREVALENCE AND PREDICTIVE FACTORS FOR THE DEVELOPMENT OF OSTEOPOROSIS IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS
Authors: C. Parlati, M. Patrone, F. Riccio, M. Annunziata, M. Brancaccio, M. L. Marchesano, A. Milone, F. Ciccia, G. Cuomo
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Despite reports of reduced bone mineral density (BMD) in international cohorts of patients with Systemic Sclerosis (SSc), the prevalence of osteoporosis in Italian patients with SSc remains unknown. According to ISTAT data for the year 2021, 7.8% of the Italian population (13.2% female, 2.1% male) reported being affected by osteoporosis, while the global prevalence of osteoporosis is 18.3% (95% CI 16.2-20.7). In the population of patients affected by SSc, the prevalence of low BMD ranges from 27% to 53.3%, while the prevalence of osteoporosis (OP) varies from 3% to 51.1%. In this study, we report dual-energy X-ray absorptiometry (DXA) scan rates in a cohort of SSc patients at a specialized outpatient clinic of a tertiary hospital. Simultaneously, we analyze the prevalence and associations of osteoporosis in screened patients. <h3>Objectives:</h3> The primary objectives of this study are to determine the prevalence of osteoporosis among Italian patients with Systemic Sclerosis (SSc) attending a specialized outpatient clinic in a tertiary hospital and to investigate potential risk factors associated with low bone mineral density (BMD) in SSc patients, including family history of osteoporosis, age, menopausal status, disease duration, specific SSc subtypes (such as diffuse form), internal organ involvement, vitamin D levels, and the presence of calcinosis. <h3>Methods:</h3> A retrospective review of medical records was conducted to determine if patients underwent DXA scans between 2016 and 2021. T scores for the lumbar spine and femoral neck, fracture history, and osteoporosis therapies were extracted. <h3>Results:</h3> In the study involving 144 patients, 70% (102 patients) underwent DXA scans. Among patients with available T-score values (n = 90), 33.0% (30 patients) had osteoporosis, while 53.3% (48 patients) had osteopenia. Potential risk factors for low BMD in SSc include a family history of osteoporosis, age, menopause, diffuse form, internal organ involvement, low vitamin D levels and the presence of calcinosis. Those participating in screening showed a longer disease duration (19.9 years vs. 15.2 years, P = 0.002), a higher incidence of calcinosis (50.5% vs. 36.4%, P = 0.028), myositis (12.6% vs. 0.7%, P &lt;0.001), synovitis (42.7% vs. 28.6%, P = 0.022), gastrointestinal involvement (76.7% vs. 47.1%, P &lt;0.001), and interstitial lung disease (53.0% vs. 40.0%, P &lt;0.001). <h3>Conclusion:</h3> We observed high rates of osteoporosis among Italian patients with SSc. Further assessments in larger prospective studies are needed to establish guidelines for formal osteoporosis screening in SSc patients and for a comprehensive evaluation of risk factors. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>